Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF

NCT01878396 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT01878396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01878396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2011
Completion date
December 31, 2017
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma